SCHEMBL773073

SCHEMBL773073

CC(C)(C)OC(=O)CCN1CCc2ccc(C#N)cc2C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 14/20 0.64
DRD3 P35462 12/20 0.59
DRD4 P21917 2/20 0.55
OPRM1 P35372 2/20 0.55
HTR1A P08908 1/20 0.47
HTR2A P28223 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR7 P34969 1/20 0.47
HRH1 P35367 1/20 0.47
HTR2B P41595 1/20 0.47
HTR1D P28221 4/20 0.46
HTR1B P28222 4/20 0.46
CYP2D6 P10635 2/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
S1PR1 P21453 1/20 0.43
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703657 0.92 DRD2 (0.56) DRD2DRD3DRD4OPRM1HTR1A
SCHEMBL1703624 0.89 DRD2 (0.53) DRD2DRD3DRD4OPRM1HTR1A
SCHEMBL774065 0.82 DRD2 (0.64) DRD2DRD3DRD4OPRM1HTR1A
SCHEMBL1602651 0.79 ESR2 (0.60) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL12269219 0.79 KMT2A (0.49) DRD2DRD3KDM4EALDH1A1MEN1
SCHEMBL29586616 0.78 NR1H2 (0.67) DRD2DRD3DRD4OPRM1MAPT
SCHEMBL2416879 0.78 NR1H2 (0.67) DRD2DRD3DRD4OPRM1MAPT
SCHEMBL7643768 0.78 DRD2 (0.61) DRD2DRD3DRD4OPRM1HTR1A
SCHEMBL771949 0.78 ALDH1A1 (0.42) DRD2DRD3HTR1AHTR2ASLC6A4
SCHEMBL798144 0.78 ALDH1A1 (0.42) DRD2DRD3HTR1AHTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376484-B1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS MERCK SERONO SA (CH) 2015-04-22 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8741923-B2 Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis MERCK SERONO SA (CH) 2014-06-03 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
EP-2376484-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS Merck Serono S.A. (CH) 2011-10-19 EP disclosed
US-20110230518-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS MERCK SERONO S.A. (CH) 2011-09-22 US disclosed
WO-2010069949-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS MERCK SERONO S.A. (CH) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230518-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS PMP22, AQP4, NDUFS3 DRD2 3423/4885DRD3 2667/4885DRD4 3453/4885
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 DRD2 553/4885DRD3 285/4885DRD4 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.